Differential in vivo activity of docetaxel plus PS-341 combination therapy in non-small cell lung carcinoma (NSCLC) xenografts.

被引：0
|
作者：
Gumerlock, PH [1 ]
Kimura, T [1 ]
Holland, WS [1 ]
Shih, CDD [1 ]
Lara, PN [1 ]
Gandara, DR [1 ]
机构：
[1] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7144
引用
收藏
页码：652S / 652S
页数：1
相关论文
共 50 条
  • [1] Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increased response in non-small cell lung carcinoma (NSCLC).
    Gumerlock, PH
    Moisan, LP
    Lau, AH
    Mack, PC
    Lara, PN
    Gandara, DR
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3809S - 3810S
  • [2] Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezotnib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC)
    Lara, P.
    Longmate, J.
    Argiris, A.
    Gitlitz, B. J.
    Mack, P. C.
    Lau, D. H.
    Koczywas, M.
    Leighl, N. B.
    Gandara, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Proeasome inhibition with bortezomib (PS-341) in combination with docetaxel (Doc) in prostate cancer (CaP) cells and xenografts.
    Farneth, NC
    Holland, WS
    Kenosi, T
    Kimura, T
    Lara, PN
    Gandara, DR
    Gumerlock, PH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 239S - 239S
  • [4] Activity of panitumumab alone and in combination with chemotherapy against mutant epidermal growth factor receptor (EGFr)-expressing non-small cell lung carcinoma (NSCLC) cell lines and xenografts.
    Bush, T
    Freeman, D
    Ogbagabriel, S
    Belmontes, B
    Kozlosky, C
    Baher, A
    Johnson, C
    Van, G
    Cerretti, D
    Radinsky, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9047S - 9047S
  • [5] RANDOMIZED TRIAL OF CONCURRENT VERSUS SEQUENTIAL DOCETAXEL PLUS BORTEZOMIB ( PS-341) IN PLATINUM-TREATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): A CALIFORNIA CANCER CONSORTIUM STUDY
    Lara, P. N.
    Longmate, J.
    Argiris, A.
    Gitlitz, B.
    Mack, P. C.
    Lau, D.
    Koczywas, M.
    Leighl, N. B.
    Gandara, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S81 - S81
  • [6] Weekly administration of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC).
    Sun, Y
    Li, J
    Wu, Y
    Li, L
    Gu, L
    Zhang, L
    Wang, J
    Zhang, X
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 698S - 698S
  • [7] Apoptotic effects of the docetaxel→OSI-774 combination in non-small cell lung carcinoma (NSCLC) cells.
    Kimura, T
    Mahaffey, CM
    Pryde, BJ
    Mack, PC
    Davies, AM
    Gandara, DR
    Gumerlock, PH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 652S - 652S
  • [8] Phase II study to evaluate the efficacy and safety of bortezomib (PS-341) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
    Ho, L.
    Li, T.
    Piperdi, B.
    Macapinlac, M.
    Rigas, J. R.
    Camacho, F.
    Perez-Soler, R.
    Gucalp, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
    Li, Tianhong
    Ho, Liawaty
    Piperdi, Bilal
    Elrafei, Tarek
    Camacho, Fernando J.
    Rigas, James R.
    Perez-Soler, Roman
    Gucalp, Rasim
    LUNG CANCER, 2010, 68 (01) : 89 - 93
  • [10] Management of unresectable non-small cell carcinoma of the lung (NSCLC)
    Cox, JD
    Le Chevalier, T
    Arriagada, R
    Choy, H
    Curran, WJ
    Fukuoka, M
    Harper, P
    Komaki, R
    Le Pechoux, C
    Lievens, Y
    Rami-Porta, R
    Ready, N
    Sause, W
    Stuschke, M
    Thatcher, N
    LUNG CANCER, 2003, 42 : S15 - S16
12345